Valuation: EnteroMedics Inc

Market Cap 14.18M 12.51M 11.84M 10.74M 20.13M 1.36B 20.33M 142M 54.73M 695M 53.24M 52.08M 2.24B P/E 2026 *
-3.71x
P/E 2027 * -2.53x
Enterprise Value 14.18M 12.51M 11.84M 10.74M 20.13M 1.36B 20.33M 142M 54.73M 695M 53.24M 52.08M 2.24B EV / Sales 2026 *
129x
EV / Sales 2027 * 70.9x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 110K 96.63K 91.43K 82.92K 155K 10.51M 157K 1.1M 423K 5.37M 411K 402K 17.27M 200K 176K 167K 151K 284K 19.19M 287K 2M 772K 9.8M 751K 735K 31.54M
Net income -3.8M -3.35M -3.17M -2.88M -5.39M -365M -5.45M -38.06M -14.67M -186M -14.27M -13.96M -599M -7.85M -6.92M -6.55M -5.94M -11.14M -753M -11.25M -78.59M -30.29M -384M -29.46M -28.82M -1.24B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-